REG - CVS Group plc - Directorate Change

CVSAnnouncement

27/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231027:nRSa4591Ra&default-theme=true

RNS Number : 4591R  CVS Group plc  27 October 2023

For Immediate
Release
                 27 October 2023

 

 

CVS Group plc

("CVS" or the "Group")

 

Directorate Change

CVS, the UK listed veterinary group and a leading provider of veterinary
services, announces that its Chair Richard Connell has taken the difficult
decision to resign with immediate effect due to ill health.

Deborah Kemp, the Group's Senior Independent Director will assume the role of
Chair for the interim period whilst the Board commences a process to appoint a
permanent successor.

The Board will make a further announcement at the appropriate time.

CEO Richard Fairman commented: "On behalf of the Board and colleagues at CVS,
I would like to thank Richard for his significant contribution during his
tenure as Chair and for his support to me personally.  Richard has played a
pivotal role in overseeing considerable growth in the Group over the past 16
years and will be sorely missed.  We wish Richard a full and speedy
recovery."

 

 

 

Contacts

CVS Group
plc
via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

 

Peel Hunt LLP (Nominated Adviser & Broker)
 
+44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

 

Berenberg (Joint
Broker)
+44 (0)20 3207 7800

Toby Flaux / Ben Wright / James Thompson / Milo Bonser

 

Camarco (Financial PR)
 

Geoffrey
Pelham-Lane
+44 (0)7733 124 226

Ginny Pulbrook
 
+44 (0)7961 315 138

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFEIFMMEDSEFS